KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

Rhea-AI Summary

KalVista Pharmaceuticals (NASDAQ: KALV) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 9:20 a.m. ET. A live webcast will be available on the company's website, along with an audio archive for 30 days post-event.

KalVista focuses on developing small molecule protease inhibitors, including KVD900 for acute hereditary angioedema (HAE) attacks and KVD824 for prophylactic HAE treatment, with significant clinical trial advancements in early 2021.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the 10^th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 9:20 a.m. ET.

A live webcast of the presentations will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalVista’s website for 30 days following the presentations.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with an expected IND filing for a Phase 2 clinical trial in the first quarter of 2021. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

For more information, please visit www.kalvista.com.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, our expectations about future clinical trial timing and results, our ability to commence or complete clinical studies and to obtain regulatory approvals for KVD900 and KVD824 to treat HAE, the future progress and success of our oral Factor XIIa program, and the sufficiency of our cash, cash equivalents and investments to fund our operations. Further information on potential risk factors that could affect our business and financial results are detailed in our annual report on Form 10-K filed on July 1, 2020, our quarterly reports on Form 10-Q, when filed, and other filings we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005112/en/

FAQ

When is KalVista Pharmaceuticals participating in the SVB Leerink Global Healthcare Conference?

KalVista Pharmaceuticals will participate in the SVB Leerink Global Healthcare Conference on February 25, 2021, at 9:20 a.m. ET.

How can I watch the KalVista Pharmaceuticals presentation at the conference?

The presentation by KalVista Pharmaceuticals will be available via a live webcast on their website.

What is the focus of KalVista Pharmaceuticals?

KalVista Pharmaceuticals specializes in developing small molecule protease inhibitors for significant unmet medical needs, particularly targeting hereditary angioedema and diabetic macular edema.

What clinical trials is KalVista currently conducting?

KalVista is conducting trials for KVD900, an on-demand therapy for acute HAE attacks, and KVD824, a prophylactic treatment for HAE.

What is KVD900 and its clinical status?

KVD900 is an oral therapy for acute hereditary angioedema attacks that completed a Phase 2 efficacy trial in February 2021, showing significant results.